These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19909829)

  • 1. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study.
    Recker RR; Ste-Marie LG; Langdahl B; Czerwinski E; Bonvoisin B; Masanauskaite D; Rowell L; Felsenberg D
    Bone; 2010 Mar; 46(3):660-5. PubMed ID: 19909829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.
    Recker RR; Weinstein RS; Chesnut CH; Schimmer RC; Mahoney P; Hughes C; Bonvoisin B; Meunier PJ
    Osteoporos Int; 2004 Mar; 15(3):231-7. PubMed ID: 14727011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
    Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
    J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
    J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.
    Bianchi G; Czerwinski E; Kenwright A; Burdeska A; Recker RR; Felsenberg D
    Osteoporos Int; 2012 Jun; 23(6):1769-78. PubMed ID: 21975558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study.
    Recker RR; Ste-Marie LG; Langdahl B; Masanauskaite D; Ethgen D; Delmas PD
    J Clin Densitom; 2009; 12(1):71-6. PubMed ID: 19084450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Delmas PD; Adami S; Strugala C; Stakkestad JA; Reginster JY; Felsenberg D; Christiansen C; Civitelli R; Drezner MK; Recker RR; Bolognese M; Hughes C; Masanauskaite D; Ward P; Sambrook P; Reid DM
    Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
    Lewiecki EM; Keaveny TM; Kopperdahl DL; Genant HK; Engelke K; Fuerst T; Kivitz A; Davies RY; Fitzpatrick LA
    J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
    Stakkestad JA; Benevolenskaya LI; Stepan JJ; Skag A; Nordby A; Oefjord E; Burdeska A; Jonkanski I; Mahoney P;
    Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Schimmer RC; Bauss F
    Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.
    Bock O; Börst H; Beller G; Armbrecht G; Degner C; Martus P; Roth HJ; Felsenberg D
    Bone; 2012 Jan; 50(1):317-24. PubMed ID: 22067902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
    Nakamura T; Ito M; Hashimoto J; Shinomiya K; Asao Y; Katsumata K; Hagino H; Inoue T; Nakano T; Mizunuma H;
    Osteoporos Int; 2015 Nov; 26(11):2685-93. PubMed ID: 26001561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous ibandronate: in the treatment of osteoporosis.
    Croom KF; Scott LJ
    Drugs; 2006; 66(12):1593-601; discussion 1602-3. PubMed ID: 16956306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.
    Dalle Carbonare L; Arlot ME; Chavassieux PM; Roux JP; Portero NR; Meunier PJ
    J Bone Miner Res; 2001 Jan; 16(1):97-103. PubMed ID: 11149495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
    Recker RR; Bare SP; Smith SY; Varela A; Miller MA; Morris SA; Fox J
    Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
    Reginster JY; Wilson KM; Dumont E; Bonvoisin B; Barrett J
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5018-24. PubMed ID: 15972582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
    Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD
    Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis.
    Riis BJ; Ise J; von Stein T; Bagger Y; Christiansen C
    J Bone Miner Res; 2001 Oct; 16(10):1871-8. PubMed ID: 11585352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.